molecules of the month

“Compound 72”

oral PRMT5 inh. for treating cancers

projected human dose of 15 mg QD w/ 6 HBD

SBDD from SAM cofactor

J. Med. Chem., Mar. 23, 2021

Merck & Co, Boston, MA

Structure of compound 72
1 min read

The Merck protein arginine methyltransferase 5 (PRMT5) inhibitor (“compound 72”) is a SAM cofactor-mimetic with a novel 5,5-fused carbon-based bicyclic scaffold. PRMT5 is an actively pursued epigenetic target for cancer with a flurry of research programs being published recently and several trials being initiated. Remarkably, compound 72 has an excellent oral PK profile in higher species with a low predicted human dose of 15 mg QD, despite having 6 hydrogen bond donors and 6 rings.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: